Viridian Therapeutics, Inc. VRDN Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number at other companies

Immunovant, Inc.IMVT

——

Krystal Biotech, Inc.KRYS

——

Aurinia PharmaceuticalsAUPH

——

Other financials

Income statement

See full

Revenue$141.0K+95.8%

Operating income-$116.2M-23.8%

Net income-$104.9M-20.7%

EPS (diluted)-$1.15-5.5%

Balance sheet

See full

Cash & equivalents$176.3M+51.7%

Total debt$36.8M+59.4%

Total equity$636.0M+5.2%

Total assets$789.0M+19.4%

Cash flow

See full

Operating cash flow-$119.7M-29.1%

CapEx$23.0K-73.3%

Free cash flow-$119.7M-29.0%

Valuation

See full

Market cap$1.91B+82.0%

Profitability

See full

Gross margin36.3%—

Operating margin-543.9%-271pp

Net margin-508.5%-254pp

FCF margin-428.4%-214pp

Returns & leverage

See full

Return on equity-58.1%+7.9pp

Debt / equity0.1×0.0×

Current ratio15.1×-4.3×

Where this comes from

Reported directly by Viridian Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.

The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viridian Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viridian Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number?: Viridian Therapeutics, Inc. (VRDN) reported share-based compensation arrangement by share-based payment award, options, outstanding, number of $16.75M in Q1 2026.
How has Viridian Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number changed year-over-year?: Viridian Therapeutics, Inc.'s share-based compensation arrangement by share-based payment award, options, outstanding, number increased by 18.6% year-over-year, from $14.12M to $16.75M.